Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 09    tags : Cancer    save search
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Published: 2021-04-09 (Crawled : 21:00) - globenewswire.com
SGEN | $228.74 0.1% 20M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
GMAB | News | $28.47 -0.32% -0.32% 460K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
JNJ | News | $148.53 -0.69% -0.14% 9.6M twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
fda cancer license
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
Published: 2021-04-09 (Crawled : 15:00) - biospace.com/
APVO | $0.6827 -7.27% -7.84% 570K twitter stocktwits trandingview |
Health Technology
 | | O: 1.99% H: 0.0% C: -5.73%
cancer research
Turning Point Therapeutics Announces New Preclinical Data for Three Drug CandidatesPresentations Planned at Annual Meeting of American Association for Cancer Research, Held Virtually April 9-14
Published: 2021-04-09 (Crawled : 15:00) - biospace.com/
TPTX | $76.01 -0.03% twitter stocktwits trandingview |
Health Technology
 | | O: -0.49% H: 0.0% C: -3.32%
presentation cancer drug research preclinical pre-clinical
US Cancer Antibody Market, Drug Price, Sales & Clinical Trials Insight to 2026: Insight on FDA Approved 57 Cancer Antibodies Available in the US Market
Published: 2021-04-09 (Crawled : 13:37) - prnewswire.com
AZN | News | $71.175 0.46% 0.46% 6.1M twitter stocktwits trandingview |
Health Technology
 | | O: 1.31% H: 0.02% C: -0.42%
sales fda clinical trials cancer antibody drug trial fda approval
Innovative Diagnostic Methods Remains Vital in the Fight Against Cancer
Published: 2021-04-09 (Crawled : 13:15) - prnewswire.com
VSTM | $9.29 -3.33% -3.44% 79K twitter stocktwits trandingview |
Health Technology
 | | O: -1.78% H: 1.81% C: 0.0%
LPTX | $3.285 2.66% 2.59% 190K twitter stocktwits trandingview |
Health Technology
 | | O: -0.55% H: 1.65% C: -1.1%
AGEN A | $7.42 14.86% 12.94% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 1.43% C: -0.18%
cancer diagnostic
Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021
Published: 2021-04-09 (Crawled : 13:15) - globenewswire.com
SANA | $8.58 6.06% 5.71% 1.2M twitter stocktwits trandingview |
| | O: -0.34% H: 0.0% C: -2.03%
cancer biotech research technology iot preclinical pre-clinical
aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting
Published: 2021-04-09 (Crawled : 13:00) - biospace.com/
LIFE | $1.595 -1.54% -1.57% 290K twitter stocktwits trandingview |
Health Technology
 | | O: -1.62% H: 9.18% C: 5.88%
cancer research breast cancer preclinical pre-clinical
ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting
Published: 2021-04-09 (Crawled : 13:00) - globenewswire.com
CCXI | News | $51.99 -0.04% twitter stocktwits trandingview |
Health Technology
 | | O: -0.77% H: 2.22% C: 1.37%
presentation cancer research
Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting
Published: 2021-04-09 (Crawled : 12:15) - globenewswire.com
RUBY | $0.057 -99.3% 760K twitter stocktwits trandingview |
Health Technology
 | | O: -0.08% H: 2.65% C: -0.95%
solid tumors ongoing phase 1 results cancer research trial phase 3 phase 2
Mersana Therapeutics Announces Initiation of UPLIFT Single-Arm Registration Strategy for UpRi in Platinum-Resistant Ovarian Cancer
Published: 2021-04-09 (Crawled : 12:15) - globenewswire.com
MRSN | $2.89 -9.97% -11.07% 3.2M twitter stocktwits trandingview |
Health Technology
 | | O: 2.24% H: 0.0% C: -3.95%
cancer ovarian cancer
Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
Published: 2021-04-09 (Crawled : 12:00) - novocure.com
NVCR | $12.35 2.45% 2.39% 1.1M twitter stocktwits trandingview |
Health Technology
 | | O: -1.14% H: 0.92% C: 0.82%
presentation cancer research
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting
Published: 2021-04-09 (Crawled : 12:00) - biospace.com/
IOVA 4 | $11.69 -1.43% -1.45% 2.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.73% H: 0.06% C: -4.28%
cancer research iot
Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting
Published: 2021-04-09 (Crawled : 12:00) - globenewswire.com
SURF | $1.07 -0.93% -1.41% 0 twitter stocktwits trandingview |
Health Technology
 | | O: 0.12% H: 1.0% C: -2.81%
immunotherapy therapy cancer research preclinical pre-clinical
Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
Published: 2021-04-09 (Crawled : 11:00) - biospace.com/
GLSI | $12.6 -4.11% -4.29% 29K twitter stocktwits trandingview |
Health Technology
 | | O: 24.77% H: 10.73% C: -14.93%
cancer breast cancer response metastatic breast cancer
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Published: 2021-04-09 (Crawled : 01:00) - prnewswire.com
GILD | $67.07 0.06% 0.06% 8.3M twitter stocktwits trandingview |
Health Technology
 | | O: -0.31% H: 0.66% C: 0.45%
treatment fda fda approval cancer breast cancer approval license
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services
BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services
MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information
RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance
Your saved searches
Save your searches and get alerts when important news are released.